Farapulse and Medtronic expect pulsed field ablation (PFA) technology to eventually dominate the US atrial fibrillation ablation catheter market, but the companies are sponsoring very different US pivotal trials of their respective PFA systems.
PFA creates short, powerful electric pulses that precisely destroy cardiac myocyte cells with irreversible electroporation. Multiple companies are developing PFA systems because preclinical studies and early clinical trials...